Trius Therapeutics: MRSA & Infection IPO Debut (TSRX)
Trius Therapeutics, Inc. (NASDAQ: TSRX) managed to come public via an initial public offering this morning. The biotech outfit is “developing innovative antibiotics for serious, life-threatening...
View ArticleA Call for a Stock Double (INHX)
Inhibitex Inc. (NASDAQ: INHX) may be slightly lower after earnings, but an analyst note is endorsing the long-term merits of the company. Zacks Research’s Jason Napodano, CFA, announced that Zacks is...
View ArticleNew Hope for Radiation & Chemo Toxicity
An FDA notice today seems to have gone almost entirely unnoticed. This is something that should have been a key stand-out event today in the world of cancer treatments even if some may have...
View ArticleClik here to view.
M&A Bonanza For Drug & Biotech in 2011 (MRK, PFE, ALXN, DNDN, HGSI, CEPH,...
The game of predicting mergers and acquisitions in the biotech and in pharma sectors is not a new one. The talk heats up, then it dies down. A deal comes, followed by another deal, and the activity...
View Article
